Genpharmasec (BOM:531592) ROCE % : 1.56% (As of Mar. 2024)

View and export this data going back to 1996. Start your Free Trial

What is Genpharmasec ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Genpharmasec's annualized ROCE % for the quarter that ended in Mar. 2024 was 1.56%.

Genpharmasec ROCE % Historical Data

The historical data trend for Genpharmasec's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genpharmasec ROCE % Chart

Genpharmasec Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

ROCE %

Get a 7-Day Free Trial

3.19

3.39

-2.46

2.03

1.53

Genpharmasec Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															5.80	2.86	2.46	3.43	1.56

Genpharmasec ROCE % Calculation

Genpharmasec's annualized ROCE % for the fiscal year that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2024 )		(A: Mar. 2023 )		(A: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2024 )		(A: Mar. 2023 )		(A: Mar. 2024 )
	=	6.597	/	( ( (198.753 - 20.637)	+	(711.258 - 27.022) )	/ 2 )
	=	6.597	/	( (178.116	+	684.236)	/ 2 )
	=	6.597	/	431.176
	=	1.53 %

Genpharmasec's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	10.696	/	( ( (0 - 0)	+	(711.258 - 27.022) )	/ 1 )
	=	10.696	/	( ( 0	+	684.236 )	/ 1 )
	=	10.696	/	684.236
	=	1.56 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Genpharmasec (BOM:531592) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Genpharmasec ROCE % Related Terms

Thank you for viewing the detailed overview of Genpharmasec's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Genpharmasec (BOM:531592) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Genpharmasec Ltd (BOM:531592) » Definitions » ROCE %

Traded in Other Exchanges

N/A

Address

Akurli Road, Office No. 104 and 105, 1st Floor, Gundecha Industrial Premises Co-op Soc. Ltd., Kandivali (East), Mumbai, MH, IND, 400101

Website

https://www.satellitecorporate.com

Genpharmasec Ltd formerly Generic Pharmasec Ltd is engaged in pharmaceutical activities and services. It operates in two reportable segments: Diagnostic Pharma Equipment which includes pharmaceutical, medicinal, and medicated preparations, patent medicines, drugs, and herbs, and in pharmaceutical, medicinal, and proprietary and industrial preparations, compounds and articles of kinds, chemists, druggists, and chemical manufacturers. Trading in the Securities segment invests in the secondary securities market. The Diagnostic Pharma Equipment segment is the key revenue generator for the group.

Genpharmasec (BOM:531592) Headlines

No Headlines